This article has been updated from a previous version to retract information originally provided by Abbott in a statement.

NEW YORK (GenomeWeb) – Abbott today announced that it has signed an exclusive licensing agreement with the Institut Curie for a biomarker for bladder cancer.

Genetic mutations in FGFR3 can be used for early detection, disease monitoring, and predicting patient outcomes in both urine and tissue-based testing. FGFR3 gene mutations are seen in about 70 percent of low-grade and 15 to 20 percent of high-grade bladder cancer cases.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.